SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-020611
Filing Date
2023-06-02
Accepted
2023-06-02 07:05:20
Documents
14
Period of Report
2023-05-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20230531.htm   iXBRL 8-K 39283
2 EX-4.1 ex-41_venrockprexfundedwar.htm EX-4.1 96079
3 EX-10.1 ex-101_venrock3a9exchangea.htm EX-10.1 46248
  Complete submission text file 0001628280-23-020611.txt   342562

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230531.xsd EX-101.SCH 1967
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230531_lab.xml EX-101.LAB 24181
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230531_pre.xml EX-101.PRE 12574
8 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230531_htm.xml XML 10023
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 23986737
SIC: 2834 Pharmaceutical Preparations